Hangzhou Huijian Technology Completes Pre-A Financing Round Led by Miracle Light Fund
VCBeat has learned that Hangzhou-based Huijian Technology recently completed its Pre-A financing round, led by Miracle Light Fund under BGI and participated in by Yanmucao Investment.
Huijian Technology, established in 2016, is a high-tech company co-founded by scientists and entrepreneurs. It is dedicated to addressing unmet clinical needs in the field of precision medicine and has developed two platform technologies at the international forefront: high-throughput clinical mass spectrometry and artificial olfactory sensing systems.
Leveraging semiconductor nanotechnology and artificial intelligence algorithms, Huijian Technology has developed high-throughput clinical mass spectrometry products that significantly outperform traditional diagnostic solutions. These products are poised to become the next-generation platform for liquid and tissue biopsies, enabling rapid mass spectrometry-based testing widely applied in tumor liquid biopsy, tumor tissue biopsy, microbial and fungal identification, SNP genotyping, drug susceptibility analysis, and medication guidance, thereby substantially expanding the clinical application scenarios of mass spectrometry.
Huijian Technology’s Bio-pSiTM tumor liquid biopsy kit, microbial mass spectrometry chip, and nucleic acid mass spectrometry chip have significantly improved the capture and enrichment efficiency of multi-omics samples as well as mass spectrometry ionization efficiency, thereby enhancing detection accuracy. In 2018, multiple products achieved satisfactory validation results at numerous clinical hospitals and third-party institutions, providing critical methodological innovations for realizing high-sensitivity, high-specificity, high-stability, and low-cost clinical testing, while laying a solid technical foundation for product commercialization.
Image from Huijian Technology
Liquid biopsy is a representative diagnostic technology of “precision medicine,” capable of spanning all stages of tumor diagnosis and treatment. Huijian Technology has built a platform based on Bio-pSiTMA novel liquid biopsy system that utilizes mass spectrometry chips and consumables as tools, centers on tumor serum peptidome profiling, and is supported by a tumor database and AI-assisted analysis. This system forms a complete, closed-loop detection platform integrating instruments, reagents, consumables, and big data analytics. With high technical barriers, it offers advantages of high throughput, high stability, high accuracy, ease of operation, and low cost, making it suitable for the screening, diagnosis, and postoperative monitoring of various types of cancer.
Currently, leveraging the company’s established serum peptide profiling database and statistical algorithms, Bio-pSiTMLiquid biopsy products for tumors can rapidly diagnose patients with rectal cancer, liver cancer, and colorectal cancer with liver metastases, achieving an accuracy rate of over 90%.
It is reported that the funds raised in this round of financing will be primarily allocated to product research and development, the construction of a tumor sample database, and the establishment of production facilities. This strategy aims to further solidify the R&D technology platform and accelerate the clinical application of its products.